X0609 4 2026-08-14 0000907654 Oruka Therapeutics, Inc. ORKA 0001333277 Quinlan Paul T false C/O ORUKA THERAPEUTICS, INC. 855 OAK GROVE AVE., SUITE 100 MENLO PARK CA 94025 0 1 0 0 General Counsel 1 Common Stock 2026-08-14 4 M 0 10000 7.8 A 41034 D Common Stock 2026-08-14 4 M 0 42000 12.5 A 83034 D Common Stock 2026-08-14 4 S 0 3630 106.0504 D 79404 D Common Stock 2026-08-14 4 S 0 10434 107.1402 D 68970 D Common Stock 2026-08-14 4 S 0 14696 107.9735 D 54274 D Common Stock 2026-08-14 4 S 0 10200 109.1131 D 44074 D Common Stock 2026-08-14 4 S 0 9193 110.0039 D 34881 D Common Stock 2026-08-14 4 S 0 3847 111.1378 D 31034 D Employee Warrant (right to buy) 7.8 2026-08-14 4 M 0 10000 0 D 2034-07-14 Common Stock 10000 89996 D Employee Stock Option (right to buy) 12.5 2026-08-14 4 M 0 42000 0 D 2035-01-21 Common Stock 42000 120500 D These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.53 to $106.51, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6) and (7) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.54 to $107.53, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.54 to $108.52, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.56 to $109.51, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.58 to $110.55, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.66 to $111.22, inclusive. The warrant vests as to 1/4 of the underlying shares on April 30, 2025 and as to 1/48 of the underlying shares monthly from April 30, 2025. The option vests as to 1/48 of the underlying shares monthly from January 1, 2025. /s/ Paul Quinlan 2026-08-14